![]() ![]() Study participants were required to have experienced one or more relapses in the year prior to entry and at least one Gd-enhancing lesion at screening. 'Teva will soon initiate Phase III studies to confirm oral laquinimod's therapeutic benefits, and we expect to begin enrollment of the trial later this year.' 'The results of this study, which once again demonstrate the efficacy and tolerability of once-daily oral laquinimod, are very exciting for the MS community - both patients and researchers,' said Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries Ltd. This extension study is followed by an open label study where patients will receive 0.6 mg laquinimod for an additional 24 months. The majority of the patients who participated in the study continued treatment with laquinimod in an ongoing, blinded 9 month extension study. The 36-week study evaluated the effect of oral daily 0.3 and 0.6 mg doses of laquinimod on MRI-monitored disease activity in patients with RRMS. 'Preliminary studies have already demonstrated the positive effect of laquinimod versus placebo, but these new data confirmed that a higher dose was even more effective and remained well tolerated.' 'Current RRMS options are effective for the treatment of the disease, but an oral therapy such as laquinimod would represent a milestone for patients as it would provide them with a completely unique, non-invasive method of drug delivery,' said Giancarlo Comi, M.D., Director of Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute, San Raffaele, Milan, Italy. These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007. +-+ | Teva: | Active Biotech: | | Dan Suesskind | Sven Andréasson | | Chief Financial Officer | President & CEO | | Teva Pharmaceutical Industries Ltd. Treatment with a 0.3 mg dose showed no statistical significant difference compared with placebo. In addition, there was a favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. LAQUINIMOD, A NOVEL ORAL COMPOUND, SHOWED SIGNIFICANT REDUCTION INĭISEASE ACTIVITY IN PAT Jerusalem, Israel and Lund, Sweden, Teva Pharmaceutical Industries Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |